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Abstract
We have previously shown that live-attenuated rabies virus (RABV)-based vaccines infect and directly activate murine and
human primary B cells in-vitro, which we propose can be exploited to help develop a single-dose RABV-based vaccine. Here
we report on a novel approach to utilize the binding of Intracellular Adhesion Molecule-1 (ICAM-1) to its binding partner,
Lymphocyte Function-associated Antigen-1 (LFA-1), on B cells to enhance B cell activation and RABV-specific antibody
responses. We used a reverse genetics approach to clone, recover, and characterize a live-attenuated recombinant RABV-
based vaccine expressing the murine Icam1 gene (rRABV-mICAM-1). We show that the murine ICAM-1 gene product is
incorporated into virus particles, potentially exposing ICAM-1 to extracellular binding partners. While rRABV-mICAM-1
showed 10-100-fold decrease in viral titers on baby hamster kidney cells compared to the parental virus (rRABV), rRABV-
mICAM-1 infected and activated primary murine B cells in-vitro more efficiently than rRABV, as indicated by significant
upregulation of CD69, CD40, and MHCII on the surface of infected B cells. ICAM-1 expression on the virus surface was
responsible for enhanced B cell infection since pre-treating rRABV-mICAM-1 with a neutralizing anti-ICAM-1 antibody
reduced B cell infection to levels observed with rRABV alone. Furthermore, 100-fold less rRABV-mICAM-1 was needed to
induce antibody titers in immunized mice equivalent to antibody titers observed in rRABV-immunized mice. Of note, only
103 focus forming units (ffu)/mouse of rRABV-mICAM-1 was needed to induce significant anti-RABV antibody titers as early
as five days post-immunization. As both speed and potency of antibody responses are important in controlling human
RABV infection in a post-exposure setting, these data show that expression of Icam1 from the RABV genome, which is then
incorporated into the virus particle, is a promising strategy for the development of a single-dose RABV vaccine that requires
only a minimum of virus.
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Introduction
Rabies virus (RABV) causes a deadly zoonotic infection that
targets and causes dysfunction within the central nervous system
(CNS) of infected hosts. Upon manifestation of symptoms, rabies is
nearly always fatal [1]. It is estimated that RABV is responsible for
55,000 human deaths per year worldwide, though this number
may be much larger [2]. Most of the disease burden is located in
the developing nations of Asia and Africa, where it is estimated
that 3.3 billion people live at risk of RABV infection [2]. Of those
infected, 40% are under 15-years-of-age [2]. Over 15 million
people receive post-exposure prophylaxis (PEP) after exposure to a
potentially infected animal [2]. If administered in a timely and
appropriate manner, current PEP is nearly 100% successful in
preventing human RABV infection. This, together with routine
vaccination of domestic animals, has resulted in a dramatic
reduction of human RABV infections in developed countries over
the last 50–60 years [3].
Current, standard PEP for previously unvaccinated, immuno-
competent individuals includes prompt wound cleaning and the
administration of four to five doses of inactivated vaccine, and in
the case of severe exposure, one dose of rabies immune globulin
(RIG) [2,4]. The efficacy of rabies PEP in developing countries
where rabies is highly endemic is hindered by high costs and a lack
of compliance, which emphasize the need for a single-dose RABV-
based vaccine to combat this global public health threat [reviewed
in [5,6]. However, it does not appear that this single-dose vaccine
will be based on currently available inactivated vaccines. A recent
study by Strady et. al. showed that a minimum of three doses of the
current inactivated RABV vaccine are required to reduce the
percentage of non- or poor-responders [less than 0.5 international
unit (IU)/ml] to just 3% in a pre-exposure setting [7]. In contrast,
live attenuated virus vaccines tend to be much more immunogenic
than their inactivated counterparts as shown in non-human
primates immunized with a replication-deficient RABV-based
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vaccine compared to the commercially available Human Diploid
Cell Vaccine (HDCV) [8].
To help delineate factors that contribute to the efficacy of live
attenuated RABV-based vaccines in the context of B cell
activation, immunity and protection, we recently showed that
live, highly attenuated RABV-based vaccine vectors induce T cell-
independent and extrafollicular T cell-dependent B cell responses
that provide protection against pathogenic RABV challenge [9].
Importantly, vaccine-induced IgM helps to prevent the spread of a
pathogenic RABV strain to the CNS and thereby contributing to
protection within days of immunization [10]. We also showed that
RABV-based vaccines efficiently infect naı¨ve primary murine and
human B cells ex-vivo, resulting in the significant upregulation of
early markers of B cell activation and antigen presentation,
including CD69, MHCII, and CD40 in murine B cells or HLA-
DR and CD40 in human B cells compared to cells treated with an
inactivated RABV-based vaccine [11]. Primary B cells infected
with a live attenuated RABV expressing ovalbumin directly prime
and stimulate naı¨ve CD4+ OT-II T cells to proliferate and to
secrete IL-2, demonstrating an important functional consequence
of B cell infection and activation by live RABV-based vaccine
vectors [11]. We propose that this direct B cell stimulation by live
RABV-based vaccines is a potential mechanism underlying their
induction of early, protective B cell responses, and that live
RABV-based vaccines designed to infect and activate B cells
represent a promising strategy to develop a single-dose post-
exposure rabies vaccine where the generation of early protective
antibody titers is critical.
To this end, in this report, we investigated the utility of
incorporating ICAM-1 into a RABV-based vaccine to target B
cells and thereby improve B cell infection, activation and anti-
RABV humoral immunity. ICAM-1 (CD54) is a transmembrane
protein of the immunoglobulin (Ig) superfamily of proteins [12]
whose binding partners include LFA-1 (CD18/CD11a) and
macrophage-1 antigen [(MAC-1); (CD18/CD11b)], both of which
are integrin family members [13], as well as the clotting protein
fibrinogen. ICAM-1 is present on various cell lineages including
leukocytes, dendritic cells (DCs), follicular dendritic cells (FDCs),
and endothelial cells [14]. LFA-1 is present on leukocytes,
including B cells, DCs, and natural killer (NK) cells [15].
Traditionally, ICAM-1 has been known to participate in cell-cell
adhesion, cell migration, and extravasation of immune cells into
sites of inflammation. However, the function of ICAM-1 in
immunity is much more complex. ICAM-1 has been implicated as
an additional costimulatory molecule involved in T cell stimulation
[16,17]. Cooperative signaling through ICAM-1 interaction may
be required for optimum response of CD4 T cells to MHCII-
presented peptide antigen [18].
In addition to the expression and function of ICAM-1 on CD4
T cells to stabilize interactions with cells bearing MHCII-
presented antigens, ICAM-1 may play important roles in viral
immunology. Specifically, ICAM-1 is naturally incorporated into
HIV-1 particles and enhances infection of LFA-1-expressing cells
by stabilizing virus:cell interactions and supporting viral uptake
[19–22], suggesting the incorporation of ICAM-1 into a virus that
can target B cells, such as attenuated RABV strains [11], may help
to enhance B cell infection and activation. In addition, Carrasco et.
al. showed that upon BCR engagement, LFA-1 on the surface of B
cells is recruited to the BCR synapse, where lipid bilayer-anchored
ICAM-1 can bind to LFA-1 and lower the antigen threshold
required for B cell activation [23]. This suggests vaccine strategies
that exploit ICAM-1/LFA-1 binding interactions on B cells may
promote effective B cell immunity with a minimal vaccine dose.
Finally, Denning et. al. showed that B cells with higher levels of
surface ICAM-1 expression, which might be the case for B cells
infected with a recombinant RABV-based vaccine expressing
ICAM-1, stimulate T cells to a greater magnitude than do B cells
expressing low levels of surface ICAM-1 [24]. Together, an
ICAM-1-based RABV vaccine holds the potential to influence B
cells responses directly by aiding in B cell infection, B cell
activation and B:T interactions, resulting in enhanced anti-RABV
antibody responses.
In this report, we exploited the potential immune enhancing
features of ICAM-1 expression in the context of RABV
vaccination. We constructed, grew and characterized a live-
attenuated rRABV-based vaccine expressing the murine Icam1
gene (rRABV-mICAM-1). When assessed in-vitro, rRABV-mI-
CAM-1 showed greater infection and activation of naive primary
mouse B cells compared to a parental rRABV-based vaccine
strain. In addition, mice primed intramuscularly with one low-dose
of rRABV-mICAM-1 showed higher, more rapid antibody
responses in-vivo as early as five days post-immunization compared
to mice primed with the same dose of rRABV. Taken together,
these data indicate that rRABV-mICAM-1 is capable of significant
infection and activation of B cells and is capable of inducing high,
early antibody titers using only one, low-dose inoculation. As such,
expression of Icam1 from the RABV genome is a promising
strategy for the development of a single-dose RABV vaccine.
Materials and Methods
Ethics statement
All animal work was reviewed and approved by the Institutional
Animal Care and Use Committee (IACUC) of Jefferson Medical
College, Thomas Jefferson University. Work was completed in
accordance with international standards [Association for Assess-
ment and Accreditation of Laboratory Animal Care (AAALAC)]
and in compliance with Public Health Service Policy on Humane
Care and Use of Laboratory Animals, The Guide for the Care and
Use of Laboratory Animals of the National Institutes of Health
(NIH).
Recombinant RABV-based vaccine construction and
recovery
rRABV is a recombinant RABV-based vaccine vector and is a
molecular clone of the SAD-B19 vaccine strain of RABV [25,26].
To construct rRABV expressing ICAM-1, the Icam1 gene of Mus
musculus encoded in pBlueScript SK+ (ATCC) was amplified by
polymerase chain reaction (PCR) with VENT polymerase [New
England Biolabs (NEB)] using forward primer JPM24 (59 –
TTTCGTACGATTATGGCTTCAACCCGTGCCAAG – 39)
(BsiWi underlined) and reverse primer JPM25 (59 – AAATCTA-
GATCAGGGAGGTGGGGCTTG – 39) (XbaI underlined). The
PCR product was digested with BsiW1 (NEB) and Xba1 (NEB) and
ligated into the plasmid prRABV that had previously been
digested with BsiW1 and Nhe1 (NEB), resulting in a plasmid named
prRABV-ICAM-1. Infectious virus was recovered following
standard methods to recover infectious RABV-based vaccines
from cDNA [25,27]. Virus was grown on baby hamster kidney
cells and then purified by ultracentrifugation over a 20% sucrose
cushion to remove soluble ICAM-1 (sICAM-1) contained in the
supernatants of the produced virus.
Vaccine characterization
Western Immunoblotting and Silver Stain. BSR cells (a
derivative of a baby hamster kidney cell line) were infected with
rRABV or rRABV-mICAM-1 at a multiplicity of infection (MOI)
of 2 focus-forming units (ffu). Uninfected cells served as negative
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controls. Cells were incubated at 37uC with 5% CO2 overnight.
Cells were lysed with RIPA buffer (Sigma-Aldrich) and cellular
debris pelleted out. Alternatively, sucrose-purified rRABV or
rRABV-mICAM-1 were lysed with RIPA buffer. Proteins were
separated via 10% SDS-PAGE and transferred to a polyvinylidene
membrane. The membrane was blocked with 5% nonfat milk
powder in 1X PBS for 1 hour at room temperature. The
membrane was incubated with 0.1 mg/ml of polyclonal goat IgG
murine ICAM-1 (R&D Systems, Inc.) in Western blot (WB) wash
buffer (PBS, 0.05% Tween 20) at 4uC overnight. The membrane
was washed three times with WB wash buffer and incubated with
secondary antibody (donkey anti-goat IgG horseradish peroxidase;
Jackson ImmunoResearch Laboratories) at 1:50,000 in WB wash
buffer for 1 hour at room temperature. The membrane was
washed three times with WB wash buffer and twice with 1X PBS
prior to performing a chemiluminescence assay (Thermo Fisher
Scientific, Inc.) as instructed by the manufacturer. To help confirm
incorporation of ICAM-1 into the RABV particle, virus particles
were first purified over a 20% sucrose cushion and the purified
virus was loaded onto a sucrose step gradient (20% to 40% in 5%
increments) and then centrifuged for 2 hours at .48K g. Virus
particles were isolated from the single band located at the 35–40%
interface. Proteins were separated via 10% SDS-PAGE and then
visualized by silver staining as described by the manufacturer
(Pierce). The gel was scanned and then converted to grayscale for
publication.
One- and Multi-Step Growth Curves. Growth kinetics of
rRABV and rRABV-mICAM-1 were determined in parallel as
previously described [28]. Briefly, BSR cells were seeded at
5.06105cells/well in 6-well plates (Corning, Inc.) in Dulbecco’s
Modification of Eagle’s Media (DMEM) containing 5% heat-
inactivated FBS/1% Penicillin/Streptomycin and infected
24 hours later with rRABV or rRABV-mICAM-1 at a MOI of
5 or 0.01 for one-step or multi-cycle growth curves, respectively.
After a two hour incubation, cells were extensively washed with
1X PBS, and supplemented with DMEM. Tissue culture
supernatants (100 ml) were harvested at the indicated time points.
Titers of infectious supernatants were determined using BSR cells
in duplicate.
In-vitro infection, activation and flow cytometry analysis
of primary murine splenocyte cultures
In-vitro infection. Single cell suspensions (106 cells/ml) from
spleens of naı¨ve female C57BL/6 mice aged 6–8 weeks were
cultured in splenocyte medium (RPMI 1640 containing 10% FBS,
50 mM beta-mercaptoethanol, 100 IU/mL Penicillin/Streptomy-
cin, and 100 mM HEPES). Cells were infected with rRABV,
rRABV-mICAM-1, or media alone (mock-infected) at a MOI of 5
and incubated at 37uC with 5% CO2 for two days in the absence
of additional mitogens to maintain the B cells and accessory
splenocytes in a resting state similar to that in which they would
exist in-vivo at the time of initial immunization [11].
Immunostaining and Flow Cytometry. Infected or mock-
infected cells were harvested two days post-infection (p.i.). Cells
were washed with FACS buffer (PBS containing 2% heat-
inactivated FBS) and stained with fluorophore-conjugated anti-
bodies. Cellular surface markers stained included CD40, CD45R
(B220), CD69, and MHCII (all from eBioscience). Cells were
washed twice with FACS buffer and fixed in 2% paraformalde-
hyde at 4uC for 30 min. Cells were washed twice with FACS
buffer and once with PermWash permeabilization buffer (BD
Biosciences) for intracellular staining. Cells were incubated in
PermWash containing FITC-conjugated RABV nucleoprotein
(N)-specific antibody (Fujirebio Diagnostics, Inc.) and phycoery-
thrin-conjugated anti-murine ICAM-1 antibody (R&D Systems,
Inc.) at 4uC for 15 min. Cells were washed twice with FACS buffer
and resuspended in FACS buffer prior to flow cytometry analysis.
Fluorescently-labeled cells were analyzed by FACScan [(BD
LSRII; BD Biosciences); (Kimmel Cancer Center, Jefferson Flow
Cytometry Facility, Jefferson Medical College, Thomas Jefferson
University)] and FlowJo software (TreeStar, Inc.) [11,29]. To
determine the effects of blocking ICAM-1 function on the surface
of virus particles, sucrose-purified rRABV-mICAM-1 virions were
incubated with anti-mICAM-1 antibody (5 mg/ml; R&D Systems,
Inc.) for 2 hours at 37uC with 5% CO2. Single cell suspensions of
murine splenocytes were prepared and treated with virus:antibody
mix for two days and then stained as described above for RABV
N, B220 and MHCII. To compare two groups of data, we used an
unpaired, two-tailed Student’s t test. (* p,0.05; **, p,0.01; ***,
p,0.001) (N = 3 completed in duplicate per group).
In-vivo immunogenicity studies
Immunization. Groups of 5 naı¨ve C57BL/6 female mice
aged 6–8 weeks (National Cancer Institute, National Institutes of
Health, Bethesda, MD) were immunized intramuscularly (i.m.) in
the hind legs with 103 ffu of rRABV or rRABV-mICAM-1.
Additional groups of mice were immunized as just described
except using a higher vaccine dose (105 ffu). PBS-immunized mice
served as negative controls.
Sample collection and immune assays. Blood was col-
lected from all mice by retro-orbital eye bleed on various days
post-immunization. Sera were analyzed for anti-RABV G total
IgG and IgM antibody titers by ELISA as previously described
[30,31]. Statistical difference in antibody titers by ELISA between
two groups of data was determined using an unpaired, two-tailed t
test and data is presented at the mean 6 SEM. *p,0.05,
**p = 0.0120.001, ***p#0.001. (N = 5 mice per group). Virus-
neutralizing antibody titers were performed using the Modified
Rapid Fluorescent Focus Inhibition Test (RFFIT) as previously
described [8,32]. Neutralization titers were normalized to IU/ml
using the World Health Organization standard human anti-rabies
immunoglobulin reference.
Results
Construction, Recovery and Characterization of a rRABV-
based Vaccine Vector Expressing Murine Icam1 Gene
(rRABV-mICAM-1)
We previously showed that live RABV-based vaccines are
highly immunogenic in mice and non-human primates [8,31,32].
We also showed that live RABV-based vaccines infect naı¨ve
primary murine and human B cells, resulting in B cell activation
and the ability of B cells to prime naı¨ve T cells to proliferate and
secrete IL-2 [11]. To determine whether B cell infection and
activation could be enhanced by expressing murine ICAM-1 from
a rRABV-based vaccine in-vitro, and whether enhanced B cell
infection and activation leads to improved anti-RABV antibody
responses in-vivo, we constructed and recovered a recombinant,
attenuated vaccine strain of RABV expressing the murine Icam1
gene (rRABV-mICAM-1, Figure 1A). Western blot analysis of
lysed BSR cells, which do not express endogenous ICAM-1 or its
binding partner LFA-1, infected with rRABV or rRABV-
mICAM-1 confirmed expression of the Icam1 gene from
rRABV-mICAM-1 but not rRABV or uninfected cells
(Figure 1B). Western blot analysis of sucrose-purified and
concentrated virus showed that the ICAM-1 protein was
incorporated into the rRABV-mICAM-1 viral particle
(Figure 1B). To help confirm that ICAM-1 was incorporated into
Developing a Single-Dose Rabies Virus Vaccine
PLOS ONE | www.plosone.org 3 January 2014 | Volume 000 | Issue 000 | e87098
the RABV particle, sucrose-purified rRABV or rRABV-mICAM-
1 were isolated on a 5% step sucrose gradient and the single band
collected. Western blot analysis detected ICAM-1 from the same
density within the gradient as RABV (Figure 1C), indicating that
ICAM-1 migrates with RABV in the sucrose gradient. To
determine whether incorporation of ICAM-1 into the virus affects
the content of viral proteins within the particle, we completed
silver staining of the step gradient-purified particles. As shown in
Figure 1D, similar levels of each viral protein were detected in
rRABV or rRABV-mICAM-1 particles indicating incorporation
of ICAM-1 does not affect the composition of viral proteins. While
it was previously determined that the RABV G cytoplasmic
domain is required for incorporation of a foreign protein into the
RABV particle [33], this requirement is not absolute, as
demonstrated here in the case of ICAM-1 expression and
elsewhere [34]. One-step and multi-cycle growth curves were
prepared to measure replication rates of rRABV-mICAM-1
compared to rRABV in BSR cells. Viral titers of supernatants
harvested from cells infected with a high multiplicity of infection
(MOI = 5; one-step growth curves) show that rRABV-mICAM-1
produces progeny virus at similar levels and with similar kinetics as
does rRABV (Figure 1E, left panel). However, viral titers of
supernatants harvested from cells infected with a low multiplicity
of infection (MOI) (MOI = 0.01; multi-cycle growth curves) show
that rRABV-mICAM-1 is slightly spread-deficient compared to
rRABV, as indicated by 10–100-fold lower viral titers (Figure 1E,
right panel). Since BSR cells are not expected to express a ligand
for mICAM-1, differences in growth kinetics most likely arise from
the insertion of a foreign gene and not due to ICAM-1 function.
Together, an infectious live RABV-based vaccine vector that
expresses the murine ICAM-1 protein from the viral genome,
which is incorporated into viral particles, was cloned and
recovered and shown to be somewhat deficient in its ability to
spread in-vitro.
rRABV-mICAM-1 Infects Primary Murine B Cells In-vitro
More Effectively Than Does rRABV
As noted previously, HIV-1 naturally incorporates ICAM-1 into
HIV-1 particles, which enhances infectivity of LFA-1-expressing
target cells [19–21]. Based on this finding, and our previous
findings that live attenuated RABV vaccine strains infect and
activate primary murine and human B cells in-vitro, we hypoth-
esized that a recombinant RABV vaccine vector that expresses
and incorporates ICAM-1 into the viral particle would promote
infection of B cells, resulting in enhanced B cell activation in-vitro.
Naı¨ve primary murine splenocytes were infected at an MOI of 5
with rRABV or rRABV-mICAM-1, or treated with medium alone
(mock infected) for two days in-vitro. No additional mitogens were
added to the culture to avoid expressing activation molecules that
could enhance sensitivity to RABV infection and activation [11].
Figure 2A shows a representative gating strategy of total live
splenocytes stained for RABV N as a marker for infection and for
cell-surface expression of B220 as a maker for B cells [9,29].
Consistent with our previous data showing that live rRABV-based
vaccines infect primary murine splenocytes [11], approximately
5% of the total splenocyte cells were infected with rRABV, which
is statistically significant compared to mock-infected cells (,1%)
(Figure 2B). However, almost 40% of the total splenocytes cells
were infected with rRABV-mICAM-1 (Figure 2B). In addition,
over 50% of the B cells in culture were infected with rRABV-
mICAM-1 compared to about 8% of the B cells infected with
rRABV, or 1% background levels in mock-infected cultures
(Figure 2C). Of note, the enhanced infection of B cells with
rRABV-mICAM-1 was largely due to ICAM-1 incorporation into
the virus particle, since pretreatment of sucrose-purified rRABV-
mICAM-1 with a neutralizing anti-ICAM-1 antibody significantly
reduced infection of B cells in culture (Figure 1D). Together, these
data indicate that expression of ICAM-1 from a rRABV-based
vaccine enhances infection of primary murine splenocytes, with a
propensity for infecting B cells.
Next, we wanted to evaluate the expression levels of ICAM-1 in
primary murine splenocytes infected with rRABV and whether
expression of ICAM-1 was increased in cultures infected with
rRABV-mICAM-1. Figure 3A shows a representative gating
strategy of total live splenocytes gated for ICAM-1 and for B220
expression. Figure 3B shows a representative strategy of B220+ B
cells gated for ICAM-1 and RABV N. Expression of ICAM-1 was
significantly increased in total mouse splenocyte cultures
(Figure 3C) treated with rRABV compared to mock-infected
cultures. This finding indicates that host-cell Icam1 gene expression
is upregulated in murine splenocytes upon infection with
attenuated RABV strains. ICAM-1 expression was significantly
enhanced in splenocytes cultures treated with rRABV-mICAM-1
compared to rRABV-infected cultures (Figure 3C). Consistent
with the pattern of ICAM-1 expression in total splenocytes
infected with rRABV or rRABV-mICAM-1, the expression of
ICAM-1 within the B cell component of the splenocyte culture was
significantly increased in cultures treated with rRABV compared
to mock-infected cells, which is statistically increased in B cells
infected with rRABV-mICAM-1 (Figure 3D). To confirm that
infection enhanced ICAM-1 expression, we analyzed total
splenocytes (Figure 3E) or gated B220+ B cells (Figure 3F) for
infection and ICAM-1 expression (i.e., RABV-N+ICAM-1+ or
B220+RABV-N+ICAM-1+). While rRABV-infected total spleno-
cytes or rRABV-infected B cells upregulated ICAM-1 expression
compared to mock-infected cultures, rRABV-mICAM-1-infected
cells showed almost 40% of the total splenocytes, or over 50% of
the B cells, upregulated ICAM-1 expression. Together, these data
indicate that attenuated RABV-based strains induce ICAM-1
expression in primary murine splenocytes, most notably in B220+
B cells, which is further enhanced by expressing ICAM-1 from
rRABV-mICAM-1.
rRABV-mICAM-1 Activates Primary Murine B cells In-vitro
More Effectively Than Does rRABV
Next we wanted to evaluate whether the increased infection
noted above in total splenocytes and B cells results in increased
activation of primary murine B cells in-vitro. Naı¨ve primary murine
splenocytes cultures were infected with rRABV or rRABV-
mICAM-1, or treated with medium alone (mock-infected). The
cells were immunostained two days later for cell-surface expression
of the activation markers, CD69, CD40 and MHCII. Figures 4A,
4C and 4E show representative gating strategies of B220+ B cells
gated for CD69, CD40, or MHCII, respectively, and for RABV N
expression. B220+ B cells infected with rRABV showed significant
upregulation of the activation markers CD69 (Figure 4B), CD40
(Figure 4D) and MHCII (Figure 4F) compared to mock-infected
cells. Moreover, the percentage of B220+ B cells infected with
rRABV-mICAM-1 that express CD69 (Figure 4B, 11%), CD40
(Figure 4D, 43%) and MHCII (Figure 4F, 45%) statistically
increased compared to B220+ B cells infected with rRABV. Of
note, increased B cell activation in response to infection with
rRABV-mICAM-1 was largely due to ICAM-1 incorporation into
the virus particle, since pretreatment of purified rRABV-mICAM-
1 with a neutralizing anti-ICAM-1 antibody significantly reduced
MHCII expression in rRABV-mICAM-1-infected B cells
(Figure 4G). Together, these data confirm our previous report
showing that attenuated RABV-based strains activate naı¨ve
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primary murine B cells, and that expressing ICAM-1 from
rRABV-mICAM-1 enhances B cell activation in RABV-infected
cells.
Kinetics Analyses Shows Enhanced Anti-RABV Antibody
Responses in Mice Immunized with a Low Dose of rRABV-
mICAM-1 Compared to Mice Immunized with rRABV
The above data indicate that rRABV-mICAM-1 infects and
activates naı¨ve primary murine B cells more effectively than does
rRABV in-vitro, suggesting that rRABV-mICAM-1 might promote
effective B cell responses in-vivo. Furthermore, ICAM-1 binding to
LFA-1 on B cells was shown to lower the antigen threshold needed
for B cell activation [23], suggesting that a low-dose of a RABV-
based vaccine in which ICAM-1 is incorporated into the viral
particle might induce potent anti-RABV B cell responses. To
investigate anti-RABV antibody responses in-vivo, mice were
immunized with a high dose (105 ffu/mouse) or a low dose
(103 ffu/mouse) of rRABV-mICAM-1 or rRABV. PBS-immu-
nized mice served as negative controls. As shown in Figure 5A,
mice immunized with 105 ffu/mouse of rRABV-mICAM-1
showed similar anti-RABV G IgG antibody titers compared mice
immunized with the same dose of rRABV at all time points tested
(Figure 5A, a–e). However, mice immunized with only 103 ffu/
mouse of rRABV-mICAM-1 showed significantly higher anti-
RABV G antibody titers as early as five days post-immunization
compared to mice similarly immunized with rRABV (Figure 5B, f–
j), which were statistically higher at all time points tested
thereafter, including 87 days post-immunization, which was the
last time point tested. Of note, mice immunized with only 103 ffu/
mouse with rRABV-mICAM-1 showed similar antibody kinetics
compared to mice immunized with 105 ffu/mouse with rRABV-
mICAM-1 or rRABV indicating that 100-fold less ICAM-1-
expressing rRABV is needed to induce similar anti-RABV G
antibody responses as the parental virus.
Low-dose rRABV-mICAM-1 Induces VNA Titers In-vivo
More Rapidly and in Higher Quantities than does rRABV
VNAs directed against the single viral transmembrane glyco-
protein are the primary correlate of protection against RABV
infection. The World Health Organization suggests that a VNA
titer greater than 0.5 international units (IU)/ml is indicative of a
satisfactory immunization [5,35–37]. Consistent with the antibody
Figure 1. Construction, recovery and characterization of a recombinant RABV-based vaccine expressing the murine Icam1 gene
(rRABV-mICAM-1). A) At the top is a parental recombinant RABV-based vaccine containing an additional transcription stop-start signal flanked by
two unique restriction sites between the G and the L genes. rRABV, which is a molecular clone of the SAD-B19 vaccine strain of RABV, was the target
to introduce the gene encoding murine ICAM-1. B). BSR cells, which are not expected to express ICAM-1 or its binding partner LFA-1, were infected
with rRABV or rRABV-mICAM-1 and lysed 48 hours later. Proteins were separated by SDS-PAGE and subjected to Western blotting with antibodies
specific for ICAM-1. A protein of the expected size for ICAM-1 was detected from lysates of rRABV-mICAM-1-infected but not from rRABV-infected BSR
cells. In parallel, sucrose-purified and concentrated virus was analyzed by western blot analysis and a protein of the expected size for ICAM-1 was
detected in the virion particle. C) Sucrose-purified rRABV-mICAM-1 was re-purified using 5% sucrose step gradient and the single band was collected
and analyzed by Western blot analysis to show ICAM-1 protein migrated within the sucrose gradient at the same density as rRABV. RABV and lysates
from uninfected BSR cells served as controls for the Western blot analyses. D) Silver staining of separated proteins from sucrose step gradient-purified
particles shows a protein at the expected size of ICAM-1 and that the incorporation of ICAM-1 into the virus particles does not affect viral protein
compositions. E) BSR cells were infected with rRABV or rRABV-mICAM-1 at a MOI of 5 (one step growth; left) or .01 (multi-cycle growth curve; right).
Aliquots of tissue culture supernatants were collected, and viral titers were determined in duplicate.
doi:10.1371/journal.pone.0087098.g001
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titers measured by ELISA in Figure 5, VNA titers were similar in
mice immunized with 105 ffu/mouse with either rRABV or
rRABV-mICAM-1 at all time points tested (data not shown).
However, VNA titers in mice immunized with only 103 ffu/mouse
of rRABV-mICAM-1 were twice the WHO limit indicative of a
satisfactory immunization by five days post-immunization
(Figure 6) while less than 0.1 IU/ml were detected in mice
immunized with 103 ffu/mouse of rRABV at the same time point.
At seven days post-immunization, over 3-fold higher VNA titers
were detected in mice immunized with 103 ffu/mouse of rRABV-
mICAM-1 compared to rRABV-immunized mice. Higher VNA
titers were subsequently detected in rRABV-mICAM-1 immu-
nized mice compared to rRABV-immunized mice at all time
points thereafter. VNA titers in mice primed with 103 ffu or
105 ffu of rRABV-mICAM-1 showed similar profiles at all time
points measured (data not shown), consistent with serum antibody
titers shown in Figure 5.
All together, we show that a recombinant RABV-based vaccine
that expresses the murine Icam1 gene infects and activates naive
primary murine B cells more effectively than the parental virus,
rRABV. Furthermore, we show that rRABV-mICAM-1 induces
significantly higher anti-RABV antibody responses in-vivo com-
pared to mice immunized with rRABV alone. VNA titers
indicative of a satisfactory immunization were detected as early
as five days post-immunization with a single dose of vaccine
containing only 103 ffu virus, suggesting expressing ICAM-1 from
live RABV-based vaccines may be an excellent single-dose RABV-
based vaccine to replace current multi-dose inactivated RABV-
based vaccines.
Discussion
In this study, we demonstrated that a recombinant RABV-based
vaccine expressing ICAM-1 (rRABV-mICAM-1), which is incor-
porated into the virus particle, infects and activates primary naı¨ve
murine B cells more effectively than the parental virus, rRABV.
Furthermore, we showed that rRABV-mICAM-1 induces signif-
icantly higher anti-RABV antibody titers as early as five days post-
infection with only a minimum of virus (i.e., 103 ffu/mouse). To
the best of our knowledge, this is the first RABV-based vaccine
strategy that exploits the immune enhancing properties of ICAM-
1.
Interestingly, ICAM-1 is upregulated in total splenocytes,
including B cells, infected with rRABV alone, indicating that
attenuated RABV-based vaccines promote the expression of cell-
derived ICAM-1. The function(s) of cell-derived ICAM-1 expres-
sion in response to live RABV vaccination is (are) not known and
were not tested directly in this study. For attenuated RABV
vaccine strains, the potential exists that the upregulation of ICAM-
1 in infected cells influences a wide range of immune functions,
Figure 2. rRABV-mICAM-1 infects primary murine splenocytes and B cells more efficiently than the parental virus, rRABV. Naı¨ve
primary murine splenocytes were infected at an MOI of 5 with rRABV or rRABV-mICAM-1, or treated with media alone (mock-infected) for two days in-
vitro. No additional mitogens were added to the culture to maintain the B cells and accessory splenocytes in a resting state similar to that in which
they would exist in-vivo at the time of initial immunization. A) Representative gating strategy of total live splenocytes stained for intracellular RABV N
as a marker for infection and for cell-surface expression of B220 as a maker for B cells. The percentage in the upper right quadrant is a representative
example of the percentage of B220+ B cells infected with the rRABV-based vaccine. B) Percent RABV N+ cells in the total live lymphocyte gate. C)
Percent RABV N+ cells in the B220+ cell population. D) Pretreatment of sucrose-purified rRABV-mICAM-1 with a neutralizing anti-ICAM-1 antibody
significantly reduced infection of B cells in culture. To compare two groups of data, we used an unpaired, two-tailed Student’s t test. (* p,0.05; **, p,
0.01; ***, p,0.001)
doi:10.1371/journal.pone.0087098.g002
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including promoting immunological synapses in APC and CD4+ T
cell interactions (i.e., the immunological synapse) [38], lowering
the antigen threshold required for B cell activation thereby
reducing the amount of antigen necessary to activate B cells [23],
or by promoting T cell activation in B:T interactions [24]. It might
be expected that virally encoded ICAM-1 would augment the
beneficial effects of ICAM-1 expression on RABV-specific B cell
immunity.
The incorporation of ICAM-1 into rRABV-mICAM-1 particles
was not expected since the cytoplasmic domain (CD) of the RABV
glycoprotein (G) is generally required for incorporation of a
foreign protein into the virion particle [39]. Nonetheless, the
requirement for the RABV CD appears not to be absolute as
shown here and elsewhere [40]. The finding that ICAM-1 is
incorporated into the rRABV-mICAM-1 particle may have
implications for vaccine design since pre-treating rRABV-
mICAM-1 particles with an ICAM-1 neutralizing antibody
reduces B cell infection and activation to levels observed with
rRABV alone. In addition, ICAM-1 is naturally incorporated into
HIV-1 particles, which promotes virus infection by stabilizing virus
adhesion to LFA-1 positive cells [21]. The potential exists that
ICAM-1 expressed on the surface of the RABV particle enhances
and/or prolongs virus:cell interactions, leading to greater virus
uptake, infection and activation of B cells that constitutively
express LFA-1. In addition, as noted above, ICAM-1 binding to
LFA-1 on B cells reduces the antigen threshold needed for B cell
activation. Indeed, we observed that rRABV-mICAM-1 induces B
cells to produce equivalent antibody titers as 100-fold more of the
parental virus, rRABV. Together, we show that attenuated
RABV-based vaccines increase ICAM-1 expression in primary
murine B cells, which can be augmented by encoding ICAM-1
into the virus genome.
We previously showed that RABV-based vaccines infect
primary murine and human B cells, resulting in B cell activation
and their ability to prime naı¨ve mouse T cells to proliferate and to
secrete IL-2. In the experiments described here, we wanted to
determine if increased infection of primary splenocytes or B cells
accompanies increased activation in response to infection with
rRABV-mICAM-1. Three activation markers were used to study
immune cell activation in the context of RABV infection. CD69 is
the earliest expressed activation marker on the surface of B and T
cells [41,42] and provides insight into the speed by which rRABV
activates primary murine B or T cells. CD40 is a costimulation/
survival molecule constitutively expressed on B cells whose
expression is upregulated upon B cell:CD4 T cell engagement
and is required for optimal B and T cell activation and
proliferation [43,44]. MHCII molecules are loaded with peptide
epitopes following internalization and processing of foreign
antigen. MHCII-peptide complexes are then expressed on the
surface of the B cell for recognition by CD4 T cells specific for the
peptide. Engagement of MHCII-peptide complexes with the TCR
is the first of two required signals for CD4 T cell activation
(reviewed in [45]). Significantly increased expression of CD40 and
MHCII on splenic B cells treated with rRABV-mICAM-1 is
indicative of an activation state where B cells are capable of
presenting antigen to CD4 T cells. In agreement with our previous
Figure 3. rRABV infection results in the upregulation of ICAM-1 expression, which is augmented by infection with rRABV-mICAM-1.
Total naı¨ve primary murine splenocytes were infected as described in Figure 2 and then stained for B220, ICAM-1, and RABV-N for analysis by flow
cytometry. A) Representative gating strategy of total live lymphocytes gated on ICAM-1 and RABV N staining. B) Representative gating strategy of
B220+ B cells gated on RABV N and ICAM-1. C) Percent ICAM-1+ cells in the total live lymphocyte population. D) Percent ICAM-1+ cells in the B220+
cell population. E) Percent RABV N+ ICAM-1+ cells in the total live lymphocyte population. D) Percent RABV N+ ICAM-1+ cells in the B220+ cell
population. To compare two groups of data, we used an unpaired, two-tailed Student’s t test. (* p,0.05; **, p,0.01; ***, p,0.001)
doi:10.1371/journal.pone.0087098.g003
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Figure 4. Infection with rRABV results in the upregulation of B cell activation markers, which are enhanced by infection with rRABV-
mICAM-1. The infected splenocyte cultures described in Figure 3 were analyzed for the activation of B cells, as measured by the upregulation of cell
surface expression of CD69, CD40 or MHCII in RABV N+ B cells. Representative gating strategy of B220+ B cells from the total live population gated on
CD69 (A), CD40 (C) or MHCII (E). The percentage of RABV N+CD69+ B cells (B), RABV N+CD40+ B cells (D) and RABV N+MHCII+ B cells (F) are indicated.
G) Pretreatment of sucrose-purified rRABV-mICAM-1 with a neutralizing anti-ICAM-1 antibody significantly reduced the expression of MHCII on the
infected B cells in culture. To compare two groups of data, we used an unpaired, two-tailed Student’s t test. (* p,0.05; **, p,0.01; ***, p,0.001)
doi:10.1371/journal.pone.0087098.g004
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data [11], we show here that the parental virus, rRABV, increases
CD69, CD40 and MHCII expression on the surface of infected B
cells. Furthermore, we show that expressing ICAM-1 from the
RABV genome significantly increases the expression of these
activation markers, suggesting ICAM-1 expression may enhance B
cell-intrinsic priming of naive CD4+ T cells to proliferate and
secrete IL-2 in the context of RABV vaccination. The influence of
ICAM-1 expression on the ability of B cells to prime T cells was
not directly studied here and remains to be experimentally
defined. Nonetheless, the activated B cell phenotype suggests a
potential role for virally encoded ICAM-1 to enhance B:T cell
interactions.
The primary correlate of vaccine-induced protection against
RABV is virus-neutralizing IgG antibodies (VNA). The WHO
considers a VNA titer of 0.5 IU/ml to be indicative of a
satisfactory immune response to RABV vaccination [5,35–37].
VNA titers in mice primed with only 103 ffu of rRABV-mICAM-1
were 2-fold higher than the presumed level of a satisfactory
immunization as early as five days post-prime inoculation, while
only background levels of VNA titers were detected in mice
immunized with an equivalent amount of rRABV. By day 7 post-
immunization, almost a 4-fold increase in VNA titers were
detected in mice immunized with 103 ffu/mouse of rRABV-
mICAM-1 compared to mice similarly immunized with rRABV.
This pattern continued for the duration of the experiment at all
time points measured. These data indicate that one low-dose of
rRABV-mICAM-1 is highly immunogenic, which is important
from a vaccine standpoint. Since similar anti-RABV IgG antibody
response were detected using 100-fold less virus (103 ffu vs.
105 ffu), this may allow for reduced manufacturing and prepara-
tion costs, helping to reduce the overall cost of RABV PEP.
The proof-of-principle studies described herein provide evi-
dence that RABV-based vaccines can be enhanced by exploiting
ICAM-1 expression. Nonetheless, due to safety concerns for the
use of a live virus as a vaccine against RABV infection, it is not
likely that a live replication-competent vaccine will replace
currently used inactivated vaccines. We have previously shown
that a replication-deficient RABV-based vaccine in which the
matrix (M) gene is deleted (rRABV-DM) is both safe and
immunogenic in mice and non-human primates [8]. Furthermore,
rRABV-DM infects and activates primary murine B cells at levels
similar as rRABV [11] and induces T cell-independent antibody
responses rapidly (neutralizing IgM and IgG) [10]. Based on the
preliminary data presented here in the context of replication-
competent rRABV-based vaccines, future work will entail testing
the potency rRABV-DM expressing ICAM-1. Furthermore, while
B cells appear to be the major target for rRABV-mICAM-1
infection, rRABV-mICAM-1 appears to also target non-B cells
more effectively than rRABV alone. Future work in the context of
rRABV-DM expressing mICAM-1 will identify a role for these
additional cell types in enhanced immunity and animal models of
post-exposure protection. Together, we have identified a potential
immune enhancing feature that may help increase the utility of
Figure 5. 100-fold less rRABV-mICAM-1 is needed to induce comparable immunity in mice compared to mice immunized with
105 ffu/mouse. C57BL/6 mice were immunized i.m. with 105 (A) or 105 (B) ffu/mouse of rRABV and blood collected at the indicated time points. Four
serial three-fold dilutions of sera were analyzed by ELISA to determine anti-RABV G antibody titers and presented as OD490 of the reciprocal serial
dilution. For comparison, sera from PBS-immunized mice (panels e and j) were tested in parallel. Statistical difference in antibody titers by ELISA
between two groups of data was determined using an unpaired, two-tailed t test and data is presented at the mean 6 SEM. *p,0.05, **p= 0.012
0.001, ***p#0.001. (N= 5 mice per group). (ffu = focus forming units; OD=optical density)
doi:10.1371/journal.pone.0087098.g005
Figure 6. Low-dose rRABV-mICAM-1 induces VNA titers in-vivo
more rapidly and in higher quantities than does rRABV. Sera
from mice immunized with a single dose 103 ffu/mouse with rRABV-
mICAM-1 or rRABV were pooled and then VNA titers measured by RFFIT
and expressed as International Units (IU/ml). Data represents equal
proportions of sera from five mice per group.
doi:10.1371/journal.pone.0087098.g006
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highly efficacious and safe RABV-based vaccines, which warrant
additional study.
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